Muls E, Rosseneu M, Blaton V, Lesaffre E, Lamberigts G, de Moor P
Eur J Clin Invest. 1984 Feb;14(1):12-5. doi: 10.1111/j.1365-2362.1984.tb00697.x.
Serum lipids and apolipoproteins (apo) A-I, A-II, and B were measured in twenty-four patients with severe primary hypothyroidism (Thyrotropin above 40 mU/l), before and during 1-thyroxine treatment. Apo A-I, A-II, and B were assayed by immunonephelometry, using monospecific antisera. The serum levels of total cholesterol (TC), of low-density lipoprotein cholesterol (LDLc), and of the major LDL apoprotein, apo B, were markedly increased in the untreated hypothyroid patients compared to the values during therapy (TC: mean +/- SD, 8.87 +/- 2.9 v. 5.48 +/- 1.6 mmol/l; LDLc: 6.66 +/- 2.6 v. 3.78 +/- 1.4 mmol/l; apo B: 1.66 +/- 0.48 v. 1.14 +/- 0.37 g/l; P less than 0.00001 for all variables). High-density lipoprotein cholesterol (HDLc) was slightly higher before than during therapy (1.58 +/- 0.7 v. 1.31 +/- 0.4 mmol/l; P less than 0.05), while the main HDL apoprotein, apo A-I, was significantly elevated (1.49 +/- 0.42 v. 1.13 +/- 0.27 g/l; P less than 0.0002). The increase of the second major HDL apoprotein, apo A-II, was less pronounced (0.33 +/- 0.1 v. 0.30 +/- 0.08 g/l; P less than 0.022). The apo A-I to apo A-II ratio, which reflects the relative concentrations of the HDL subfractions HDL2 and HDL3, was significantly higher before than during treatment (P less than 0.0006). Serum triglyceride levels were moderately elevated in the untreated hypothyroid patients (1.34 +/- 0.6 v. 0.95 +/- 0.4 mmol/l; P less than 0.002). The small decrease in body weight during therapy did not correlate with the changes of the various lipid and apoprotein parameters.(ABSTRACT TRUNCATED AT 250 WORDS)
对24例严重原发性甲状腺功能减退症患者(促甲状腺激素高于40 mU/l)在左甲状腺素治疗前及治疗期间测定了血脂及载脂蛋白A-I、A-II和B。采用单特异性抗血清通过免疫比浊法测定载脂蛋白A-I、A-II和B。与治疗期间的值相比,未经治疗的甲状腺功能减退患者的总胆固醇(TC)、低密度脂蛋白胆固醇(LDLc)以及主要的低密度脂蛋白载脂蛋白apo B的血清水平显著升高(TC:平均值±标准差,8.87±2.9对5.48±1.6 mmol/l;LDLc:6.66±2.6对3.78±1.4 mmol/l;apo B:1.66±0.48对1.14±0.37 g/l;所有变量P均小于0.00001)。高密度脂蛋白胆固醇(HDLc)在治疗前略高于治疗期间(1.58±0.7对1.31±0.4 mmol/l;P小于0.05),而主要的高密度脂蛋白载脂蛋白apo A-I显著升高(1.49±0.42对1.13±0.27 g/l;P小于0.0002)。第二主要的高密度脂蛋白载脂蛋白apo A-II的升高不太明显(0.33±0.1对0.30±0.08 g/l;P小于0.022)。反映高密度脂蛋白亚组分HDL2和HDL3相对浓度的apo A-I与apo A-II的比值在治疗前显著高于治疗期间(P小于0.0006)。未经治疗的甲状腺功能减退患者的血清甘油三酯水平中度升高(1.34±0.6对0.95±0.4 mmol/l;P小于0.002)。治疗期间体重的小幅下降与各种脂质和载脂蛋白参数的变化无关。(摘要截短至250字)